CD177 and ovarian carcinoma: To target ovarian cancer, an oncolytic adenovirus was engineered so that its capsid incorporated a specific arginine–glycine–aspartic acid (RGD) protein motif so that it could bind to αvβ3 and αvβ5 (34) since these cell surface receptors are overexpressed in ovarian cancer (35).